MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)

18.49
+4.15 (28.94%)
NASDAQ · Last Trade: Jan 10th, 4:41 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its lead drug candidate, sonelokimab. The Swiss biotech company announced on January 8, 2026, that a successful Type B meeting with the U.
Via MarketMinute · January 9, 2026
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversationsstocktwits.com
Via Stocktwits · January 9, 2026
These stocks are gapping in today's sessionchartmill.com
Via Chartmill · January 8, 2026
Why Did MLTX Stock Jump 45% In Pre-Market Today?stocktwits.com
The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.
Via Stocktwits · January 8, 2026
MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026stocktwits.com
Via Stocktwits · November 13, 2025
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgradesstocktwits.com
Via Stocktwits · September 29, 2025
Get insights into the top gainers and losers of Thursday's pre-market session.chartmill.com
Via Chartmill · January 8, 2026
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crashfool.com
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via The Motley Fool · November 28, 2025
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crashfool.com
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via The Motley Fool · November 27, 2025
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Outfool.com
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.
Via The Motley Fool · November 18, 2025
The Best AI for Picking Stocks, Ranked by Performancemarketbeat.com
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.
Via MarketBeat · October 22, 2025
Which stocks have an unusual volume on Monday?chartmill.com
Volume analysis on 2025-10-06: stocks with an unusual volume in today's session.
Via Chartmill · October 6, 2025
Top 3 Health Care Stocks That Are Preparing To Pump In Q4benzinga.com
Via Benzinga · October 6, 2025
Unusual volume stocks are being observed in Friday's session.chartmill.com
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via Chartmill · October 3, 2025
Unusual volume stocks are being observed in Thursday's session.chartmill.com
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · October 2, 2025
Unusual volume stocks are being observed in Wednesday's session.chartmill.com
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · October 1, 2025
MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upsidestocktwits.com
Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.
Via Stocktwits · September 30, 2025
Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Downchartmill.com
U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by disastrous trial results. Meanwhile, macro tension builds with a potential U.S. government shutdown and Friday’s key jobs report looming.
Via Chartmill · September 30, 2025
Wolfspeed, Tilray, Robinhood, Etsy, And Moonlake Immunotherapeutics: Why These 5 Stocks Are On Investors' Radars Todaybenzinga.com
U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to 46,316.07. These are the top stocks that gained the attention of retail traders and investors throughout the day.
Via Benzinga · September 29, 2025
Crude Oil Falls Sharply; Carnival Posts Upbeat Earningsbenzinga.com
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.
Via Benzinga · September 29, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
Via Benzinga · September 29, 2025
Nasdaq Jumps 150 Points; US Pending Home Sales Risebenzinga.com
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
Via Benzinga · September 29, 2025
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatmentinvestors.com
MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug.
Via Investor's Business Daily · September 29, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Via Benzinga · September 29, 2025
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.
Via Benzinga · September 29, 2025